Stratos Wealth Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

Stratos Wealth Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-117,721	Closed	-$2.75M	–	624
2025 Q4	$2.75M	Buy	117,721 +20,628	+21%	+$460K	0.13%	170
2025 Q3	$1.91M	Buy	97,093 +9,233	+11%	+$190K	0.09%	226
2025 Q2	$1.91M	Buy	87,860 +4,385	+5%	+$104K	0.1%	213
2025 Q1	$2.02M	Buy	+83,475	New	+$1.88M	0.11%	177

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Stratos Wealth Advisors's CPRX Position: Q1 2026 in Review

Stratos Wealth Advisors sold out of Catalyst Pharmaceutical (CPRX) in Q1 2026, closing a stake of 117,721 shares — an estimated $2.75M sold.

Stratos Wealth Advisors first reported a position in CPRX in Q1 2025 and held it in 4 quarters. The position peaked at $2.75M in Q4 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

Stratos Wealth Advisors reported no remaining Catalyst Pharmaceutical position as of Q1 2026 after selling out during the quarter.
Stratos Wealth Advisors sold 117,721 Catalyst Pharmaceutical shares in Q1 2026, an estimated $2.75M.
Stratos Wealth Advisors first reported a position in Catalyst Pharmaceutical in Q1 2025 and held it in 4 quarters.
Stratos Wealth Advisors's Catalyst Pharmaceutical position peaked at $2.75M in Q4 2025.
380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Stratos Wealth Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.